IXEMPRA® (ixabepilone)
Advanced Ovarian Cancer (platinum-resistant/refractory)
Key Facts
About R-Pharm US
R-Pharm US is a private, commercial-stage biopharmaceutical company with a focus on oncology and chronic autoimmune diseases. The company has built its portfolio through strategic acquisitions and in-licensing, notably commercializing IXEMPRA® for metastatic breast cancer and episil® for oral mucositis pain. While its original description mentions a discovery platform for novel prodrugs, current public-facing activities emphasize the commercialization of existing specialty medicines and the clinical development of IXEMPRA® in new indications like ovarian cancer. The company operates with a fully integrated model from development to commercialization.
View full company profileAbout R-Pharm US
R-Pharm US is a private, commercial-stage biopharmaceutical company with a focus on oncology and chronic autoimmune diseases. The company has built its portfolio through strategic acquisitions and in-licensing, notably commercializing IXEMPRA® for metastatic breast cancer and episil® for oral mucositis pain. While its original description mentions a discovery platform for novel prodrugs, current public-facing activities emphasize the commercialization of existing specialty medicines and the clinical development of IXEMPRA® in new indications like ovarian cancer. The company operates with a fully integrated model from development to commercialization.
View full company profile